Effect of first-line molecular targeted agents on the efficacy of second-line bevacizumab-containing regimen for metastatic colorectal cancer.

被引：0
|
作者：
Hasegawa, Hiroko
Taniguchi, Hiroya
Mitani, Seiichiro
Komori, Azusa
Masuishi, Toshiki
Narita, Yukiya
Kadowaki, Shigenori
Ura, Takashi
Andoh, Masashi
Muro, Kei
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan
[2] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.748
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
748
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Bevacizumab, Aflibercept or Ramucirmab combined with chemotherapy as second-line treatment for metastatic colorectal cancer following progression with Bevacizumab in first-line therapy: A systematic review and indirect comparison.
    Zhang, Jianwei
    Cai, Yue
    Hu, Huabin
    Ling, Jiayu
    Xiao, Jian
    Deng, Yanhong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Metastatic colorectal cancer:: First- and second-line treatment in 2005
    Rougier, P
    Lepère, C
    [J]. SEMINARS IN ONCOLOGY, 2005, 32 (06) : S15 - S20
  • [43] Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer
    Varol, Umut
    Oktay, Esin
    Yildirim, Mustafa
    Surmeli, Zeki Gokhan
    Dirican, Ahmet
    Meydan, Nezih
    Karaca, Burcak
    Karabulut, Bulent
    Uslu, Ruchan
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 166 - 170
  • [44] Real-world direct healthcare costs for metastatic colorectal cancer patients treated with cetuximab vs. bevacizumab containing regimen in first-line, or sequentially in first- and second-line, from a US private payer perspective
    Johnston, S.
    Wilson, K.
    Riehle, E.
    Varker, H.
    Juneau, P.
    Sommer, N.
    Ogale, S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S182 - S182
  • [45] Irinotecan as a second line chemotherapy in advanced and metastatic colorectal cancer. Is that appropriate regimen?
    Chilikidi, KY
    Lazarev, AF
    Doty, IN
    [J]. CLINICAL CANCER RESEARCH, 1999, 5 : 3775S - 3775S
  • [46] Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer.
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Mizunuma, Nobuyuki
    Shinozaki, Eiji
    Ogura, Mariko
    Ozaka, Masato
    Takagi, Koichi
    Yamaguchi, Toshiharu
    Hatake, Kiyohiko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [47] KRAS mutation status to predict response in first-line capox and bevacizumab therapy for metastatic colorectal cancer.
    Yone, You
    Abdallah, Mohammad
    Tahir, Saad Sabih
    Cellek, Selim
    Zhang, Jufen
    Lester, Yvonne
    Shillito, Lauren
    Child, Jennifer
    Dawson, Lizzie
    Singizi, Bryan
    Bustin, Stephen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [48] The timing of targeted therapy initiation in metastatic sarcoma as an adjuvant to first-line chemotherapy or a second-line agent
    Huang, Yujing
    He, Aina
    Tang, Lina
    Cheng, Xue
    Shen, Zan
    Yao, Yang
    Min, Daliu
    [J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (08): : 9095 - 9103
  • [49] TITULO: RESULTS OF BEVACIZUMAB IN COMBINATION WITH FIRST LINE AND SECOND LINE CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER
    Castano, A.
    Aristizabal, N.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 78 - 78
  • [50] Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.
    Sobrero, A.
    Ackland, S.
    Carrion, R. P.
    Chiara, S.
    Clarke, S.
    Giron, C. G.
    Langer, B.
    Zurlo, A.
    Young, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
12345